Aprea Therapeutics Secures $30M in Oversubscribed Private Placement
Event summary
- Aprea Therapeutics closed a $30M private placement on March 31, 2026, led by Soleus Capital and other new investors.
- The offering included pre-funded warrants for 37.2M shares and warrants for another 37.2M shares, exercisable at $0.683 per share.
- Proceeds will fund general corporate purposes and R&D expenses, with a focus on advancing the ACESOT-1051 study.
- The company plans to enroll at least 50 patients with uterine serous carcinoma and platinum-resistant ovarian cancer.
The big picture
Aprea Therapeutics' successful $30M private placement reflects growing investor confidence in the potential of its lead candidate, APR-1051, for treating biomarker-defined cancers. The oversubscription suggests strong interest in precision oncology, particularly in targeting vulnerabilities associated with cancer cell mutations. The company's focus on expanding evaluation in biologically selected tumor populations aligns with broader industry trends toward personalized medicine and biomarker-driven clinical development.
What we're watching
- Clinical Progress
- The pace at which Aprea Therapeutics advances the ACESOT-1051 study and enrolls patients in biomarker-defined populations.
- Investor Confidence
- Whether the oversubscription of the private placement translates into sustained investor interest and future funding rounds.
- Regulatory Pathway
- How the company's strategy of focusing on specific tumor populations will impact the regulatory approval process for APR-1051.
Related topics